Vijay Pande (L) and Jorge Conde
May 9, 2022 09:47 AM EDTUpdated May 11, 12:19 PM
People
AI
In Focus

Is this Sil­i­con Val­ley duo the fu­ture of biotech?

Jason Mast

Editor

SAN FRAN­CIS­CO — Sev­en years ago, Sil­i­con Val­ley’s brash­est ven­ture cap­i­tal­ist in­vit­ed a soft-spo­ken Stan­ford bio­physi­cist out for pan­cakes not far from here, plan­ning to make …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times